Prinsen, Joseph K.
Kannankeril, Prince J.
Sidorova, Tatiana N.
Yermalitskaya, Liudmila V.
Boutaud, Olivier
Zagol-Ikapitte, Irene
Barnett, Joey V.
Murphy, Matthew B.
Subati, Tuerdi
Stark, Joshua M.
Christopher, Isis L.
Jafarian-Kerman, Scott R.
Saleh, Mohamed A.
Norlander, Allison E.
Loperena, Roxana
Atkinson, James B.
Fogo, Agnes B.
Luther, James M.
Amarnath, Venkataraman
Davies, Sean S.
Kirabo, Annet
Madhur, Meena S.
Harrison, David G.
Murray, Katherine T.
Funding for this research was provided by:
National Institutes of Health (CA68485)
National Institutes of Health (DK20593)
National Institutes of Health (DK58404)
National Institutes of Health (DK59637)
National Institutes of Health (EY08126)
National Institutes of Health (UL1 TR000445)
U.S. Food and Drug Administration
Vanderbilt University (14/232,615)
University of Sharjah
National Institute of General Medical Sciences (T32 GM007569)
American Heart Association
National Center for Advancing Translational Sciences
National Institute on Aging (5R44AG005184)
National Heart, Lung, and Blood Institute (HL096844)
National Heart, Lung, and Blood Institute (HL133127)
National Heart, Lung, and Blood Institute (K01HL130497)
This article is maintained by: Elsevier
Article Title: Highly Reactive Isolevuglandins Promote Atrial Fibrillation Caused by Hypertension
Journal Title: JACC: Basic to Translational Science
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jacbts.2020.04.004
Content Type: article
Copyright: © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.